Cell Proliferation News and Research

RSS

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.

23 Nov 2013

Study confirms therapeutic potential of inhibiting Aurora-A in cancer treatment

Aurora-A is a protein involved in the cell division process that is highly expressed or synthesised in a large number of human cancers, especially in those associated with a bad prognosis. Several pharmaceutical companies have recently developed these protein inhibitors, although the therapeutic and physiological effects that blocking Aurora-A might have on adult tissues are still unknown.

19 Nov 2013

Bleach solution could provide new way to treat skin damage

Processes that age and damage skin are impeded by dilute bleach solution, according to a new study by researchers at the Stanford University School of Medicine.

16 Nov 2013

Novel discovery of RUNX3 gene provides new insights on defence mechanism against lung cancer

Novel discovery relating to the function of RUNX3 gene provides new insights on human defence mechanism against early stages of lung cancer development

13 Nov 2013

Study suggests that therapies targeting KDM2A may benefit subset of NSCLS patients

Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer deaths worldwide. Current therapies that target cellular kinases have been effective for some patients: however, many individuals with NSCLS do not respond.

11 Nov 2013

TGen-led study reveals viable target to prevent spread of brain cancer

A cellular pathway interaction known as TWEAK-Fn14, often associated with repair of acute injuries, also is a viable target for drug therapy that could prevent the spread of cancer, especially brain cancer, according to a study led by the Translational Genomics Research Institute.

11 Nov 2013

Buyang Huanwu Decoction regulates neural stem cell behavior in ischemic brain

The traditional Chinese medicine Buyang Huanwu Decoction has been shown to improve the neurological function of patients with stroke.

7 Nov 2013

New drug combination therapy effectively kills cancer cells

Results from a recent preclinical study have shown that a new drug combination therapy being developed at Virginia Commonwealth University Massey Cancer Center effectively killed colon, liver, lung, kidney, breast and brain cancer cells while having little effect on noncancerous cells. The results lay the foundation for researchers to plan a future phase 1 clinical trial to test the safety of the therapy in a small group of patients.

6 Nov 2013

Researchers identify factor that promotes metastasis of colon tumors

Tumors become highly malignant when they acquire the ability to colonize other tissues and form metastases. Researchers at Ludwig-Maximilians-Universitaet (LMU) in Munich have identified a factor that promotes metastasis of colon tumors - and presents a possible target for therapy.

5 Nov 2013

LMU researchers identify a factor that promotes metastasis of colon tumors

Tumors become highly malignant when they acquire the ability to colonize other tissues and form metastases. Researchers at Ludwig-Maximilians-Universitaet in Munich have identified a factor that promotes metastasis of colon tumors - and presents a possible target for therapy.

4 Nov 2013

Scientists uncover new mechanism through which gene expression is regulated

A new study by Weill Cornell Medical College scientists reveals a mechanism through which the expression of genes is controlled -- a finding that highlights genetic mutations that can impair the timing of gene expression.

31 Oct 2013

Prana's PBT2 effective in reversing memory, learning losses associated with aging process

Prana Biotechnology, a leading global developer of first-in-class treatments for neurodegenerative disease, has today announced the publication of an article in the peer reviewed Aging Cell showing the effects of PBT2 on neurogenesis and in reversing the memory and learning losses associated with the aging process, in normal (ie non transgenic) old mice.

31 Oct 2013

3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced the acquisition of patents for DJ5, a novel non-TZD PPARgamma agonist with potential to retard progressive renal failure in patients with autosomal dominant polycystic kidney disease ("ADPKD').

29 Oct 2013

DPP-4 inhibitors may reduce risk of autoimmune diseases

Dipeptidyl peptidase-4 inhibitors commonly used to control blood sugar levels in people with type 2 diabetes may also reduce the risk of autoimmune diseases in these patients, according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Diabetic patients may require higher doses of metformin to achieve same anti-cancer activity

A University of Colorado Cancer Center study published online this month in the journal Cell Cycle shows that breast cancer cell growth, motility and aggression is promoted by excess glucose, as experienced by patients with diabetes and metabolic syndrome.

25 Oct 2013

New investigational drug offers potential treatment option for lung cancer

PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

21 Oct 2013

Cell Therapeutics presents preclinical study results of PIXUVRI at AACR-NCI-EORTC meeting

Cell Therapeutics, Inc. (CTI) today announced the presentation of findings from a preclinical study of PIXUVRI® (pixantrone) that suggest its mechanism of inducing tumor cell death is novel and distinct from that of anthracyclines such as doxorubicin.

21 Oct 2013

New small-molecule inhibitor shows promising results in drug-resistant melanoma, breast cancer

LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, and based on these preclinical results, several phase I clinical trials were launched recently, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 19-23.

21 Oct 2013

Study: Pds5 proteins modulate behavior of cohesins to ensure proper division of cells

Cohesins are protein complexes that join the two copies of each chromosome-called sister chromatids-to ensure that they are shared fairly between the daughter cells during cell division. In this way, each daughter cell receives exactly the same genetic information from the parent cell.

19 Oct 2013

Researchers find novel drug target for anaplastic thyroid carcinomas

Anaplastic thyroid carcinomas are aggressive tumors that do not respond to traditional radio- or chemotherapeutic agents, and there currently is no cure or effective treatment available. Median survival from diagnosis is 5 months, and although ATC accounts for only 1.7% of all thyroid cancers in the U.S., it is responsible for a large proportion of thyroid cancer-related deaths.

17 Oct 2013

Cell Proliferation News and Research

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

Study confirms therapeutic potential of inhibiting Aurora-A in cancer treatment

Bleach solution could provide new way to treat skin damage

Novel discovery of RUNX3 gene provides new insights on defence mechanism against lung cancer

Study suggests that therapies targeting KDM2A may benefit subset of NSCLS patients

TGen-led study reveals viable target to prevent spread of brain cancer

Buyang Huanwu Decoction regulates neural stem cell behavior in ischemic brain

New drug combination therapy effectively kills cancer cells

Researchers identify factor that promotes metastasis of colon tumors

LMU researchers identify a factor that promotes metastasis of colon tumors

Scientists uncover new mechanism through which gene expression is regulated

Prana's PBT2 effective in reversing memory, learning losses associated with aging process

3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients

DPP-4 inhibitors may reduce risk of autoimmune diseases

Diabetic patients may require higher doses of metformin to achieve same anti-cancer activity

New investigational drug offers potential treatment option for lung cancer

Cell Therapeutics presents preclinical study results of PIXUVRI at AACR-NCI-EORTC meeting

New small-molecule inhibitor shows promising results in drug-resistant melanoma, breast cancer

Study: Pds5 proteins modulate behavior of cohesins to ensure proper division of cells

Researchers find novel drug target for anaplastic thyroid carcinomas

Event Guide: 3rd Annual TRP Supply Chain & Manufacturing Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News